Technical Analysis for ERAS - Erasca, Inc
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
Inside Day | Range Contraction | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Oversold Stochastic | Weakness | -2.59% | |
Lower Bollinger Band Walk | Weakness | 1.62% | |
Oversold Stochastic | Weakness | 1.62% | |
Stochastic Buy Signal | Bullish | 5.03% | |
Spinning Top | Other | 5.03% | |
NR7 | Range Contraction | 5.03% |
Alert | Time |
---|---|
Possible NR7 | about 11 hours ago |
Possible Inside Day | about 11 hours ago |
Down 3% | about 13 hours ago |
60 Minute Opening Range Breakdown | about 15 hours ago |
Down 2 % | about 15 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/09/2024
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of NSCLC, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. The company was incorporated in 2018 and is headquartered in San Diego, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Acute Myeloid Leukemia Colorectal Cancer Enzymes Tyrosine Kinase Receptors Oncogenes NSCLC Non Small Cell Lung Carcinoma Metastatic Solid Tumors Bemcentinib Ras Gtpase Ptpn11
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Acute Myeloid Leukemia Colorectal Cancer Enzymes Tyrosine Kinase Receptors Oncogenes NSCLC Non Small Cell Lung Carcinoma Metastatic Solid Tumors Bemcentinib Ras Gtpase Ptpn11
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 3.375 |
52 Week Low | 1.51 |
Average Volume | 868,813 |
200-Day Moving Average | 2.20 |
50-Day Moving Average | 2.10 |
20-Day Moving Average | 2.05 |
10-Day Moving Average | 1.94 |
Average True Range | 0.15 |
RSI (14) | 41.86 |
ADX | 18.81 |
+DI | 24.94 |
-DI | 21.88 |
Chandelier Exit (Long, 3 ATRs) | 2.15 |
Chandelier Exit (Short, 3 ATRs) | 2.18 |
Upper Bollinger Bands | 2.36 |
Lower Bollinger Band | 1.73 |
Percent B (%b) | 0.23 |
BandWidth | 30.61 |
MACD Line | -0.07 |
MACD Signal Line | -0.04 |
MACD Histogram | -0.027 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 2.02 | ||||
Resistance 3 (R3) | 2.02 | 1.99 | 1.99 | ||
Resistance 2 (R2) | 1.99 | 1.95 | 1.98 | 1.98 | |
Resistance 1 (R1) | 1.93 | 1.93 | 1.92 | 1.93 | 1.98 |
Pivot Point | 1.90 | 1.90 | 1.89 | 1.89 | 1.90 |
Support 1 (S1) | 1.84 | 1.86 | 1.83 | 1.84 | 1.78 |
Support 2 (S2) | 1.81 | 1.84 | 1.80 | 1.78 | |
Support 3 (S3) | 1.75 | 1.81 | 1.77 | ||
Support 4 (S4) | 1.75 |